Ben advises on matters relating to both small molecule drugs and biologics for a variety of life sciences clients. He has a particular interest in the life sciences sector due to his background in chemistry. Prior to joining Bristows, Ben completed a masters in organic chemistry and published his work on transition-metal-free synthetic methodology in Angewandte Chemie International. 

Ben has significant UK trial experience, including the preparation of expert reports, having advised on the successful defence of two High Court invalidity challenges from the start of proceedings through to judgment. Ben also works on pre-litigation strategic issues, the coordination of multi-jurisdiction patent litigation, freedom to operate analysis and regulatory issues.   

Ben’s work highlights include: 

• Accord v Novartis – acted for Novartis in the successful high court defence and enforcement of their combination patent and corresponding SPC protecting the blockbuster heart failure medicine, Entresto® (sacubitril/valsartan). Coordination of this defence with parallel actions in other European countries. 
• Celltrion v Genentech & Novartis – acted for Genentech and Novartis in the successful high court defence and enforcement of their patent relating to a concentrated liquid formulation of XOLAIR® (omalizumab). 
• Les Laboratoires Servier v Apotex – acted for Les Laboratoires Servier in a UK damages inquiry following its Supreme Court dispute with Apotex.  
• Advised on regulatory issues, including New Active Substance status, for a small molecule compound.  
• Multi-jurisdictional coordination of patent rights protecting oncology products. 
• Conducted multi-product FTO analysis for a major consumer goods company and advised on launch strategy.   

Prior to joining Bristows in 2023, Ben completed his training contract with a magic circle law firm.